Clinical Trials Directory

Trials / Completed

CompletedNCT04582929

Neubotulinum Toxin Injection in Cerivical Dystonia

24-Week Prospective, Double-Blinded, Randomized, Cross-over Design in Multicenter Study of 50 Unit of Neubotulinum Toxin Type A (Neuronox) and 100 Unit of Neubotulinum Toxin Type A (Neuronox) Injection for Cervical Dystonia in Thai Patients

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
50 (actual)
Sponsor
Department of Medical Services Ministry of Public Health of Thailand · Other Government
Sex
All
Age
20 Years – 100 Years
Healthy volunteers
Accepted

Summary

24-Week Prospective, Double-Blinded, Randomized, Cross-over design in Multicenter Study of 50 unit of Neubotulinum Toxin Type A (Neuronox) and 100 unit of Neubotulinum Toxin Type A (Neuronox) injection for Cervical Dystonia in patient diagnosed with cervical dystonia according to clinical diagnosis. It was designed to evaluate the efficacy, safety, tolerability, quality of life and the comparesion the improvement after treatment by of 50 unit of Neubotulinum Toxin Type A (Neuronox) and 100 unit of Neubotulinum Toxin Type A (Neuronox) injection.

Detailed description

Three documented studies showed the clinical use of botulinum toxin for migraine prophylaxis.(26) Neubotulinum Toxin Type A, (Neu-BoNT/A), (Neuronox® ) (Medytox Inc, Ochang-eup, Cheongwon-gu, Cheongju-si, Chungcheongbuk-do, Republic of Korea), also known as Meditoxin in Korea, is a newly manufactured BoNT-A (Neu-BoNT/A) that was developed to provide features close to onabotulinum toxin A (5). Neuronox was tested in a murine model, and its effect on muscle force generation was equivalent to Botox® (ona-BoNT/A) (6). A previous multicenter randomized controlled trial showed that Neuronox and Botox® have equivalent efficacy and safety for the treatment of spastic equinus in children with cerebral palsy (6). However, 50 unit of Neubotulinum Toxin Type A (Neuronox) and 100 unit of Neubotulinum Toxin Type A (Neuronox) has not yet been investigated in cervical dystonia. This study is the extension of the NCT03805152

Conditions

Interventions

TypeNameDescription
DRUGNeuronox ® InjectionNeuronox ® 50 or 100 unit intramuscular injection

Timeline

Start date
2019-01-03
Primary completion
2021-04-30
Completion
2021-05-30
First posted
2020-10-12
Last updated
2021-09-17

Locations

4 sites across 1 country: Thailand

Source: ClinicalTrials.gov record NCT04582929. Inclusion in this directory is not an endorsement.